Asia Pacific Monoclonal Antibodies (mAbs) Market 2020-2030 by Source (Human, Humanized, Chimeric, Murine), Category (Branded, Biosimilar), Production Type (In Vitro, In Vivo)
(Excel Data Sheet: $1,500)
The report cover may be different from the image shown.
- The product will be delivered as a PDF file by Email within 48 business hours upon receiving an order.
- To learn more about the report, please Download Free Sample Pages and Download Excel Datasheet Sample. The report will be updated before delivery, so that the most recent historic year is the base year and forecast covers 5-10 years over the base year.
- Please Contact Us for any question, custom research, and current discount. It is possible now to buy a part of the report such as chapters, sections, data tables or figures.
By clicking the Add to Shopping Cart button, you certify to agree with our Terms of Service.
Asia Pacific monoclonal antibodies market will grow by 12.8% annually with a total addressable market cap of $414 billion over 2021-2030 owing to the increasing incidences of new cancer cases and other diseases, growth in geriatric population, increasing pharmaceutical R&D spending, upsurge in healthcare expenditure, and the rising adoption of cost-efficient biosimilar monoclonal antibodies.
Highlighted with 31 tables and 51 figures, this 108-page report “Asia Pacific Monoclonal Antibodies (mAbs) Market 2020-2030 by Source (Human, Humanized, Chimeric, Murine), Category (Branded, Biosimilar), Production Type (In Vitro, In Vivo), Application (Cancer, Autoimmune, Inflammatory), End User, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific monoclonal antibodies market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2030 with 2019 as the base year (Year 2020 is not appropriate for research base due to the outbreak of COVID-19).
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific monoclonal antibodies market in every aspect of the classification from perspectives of Source, Category, Production Type, Application, End User, and Country.
Based on Source, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
• Human
• Humanized
• Chimeric
• Murine
Based on Category, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
• Branded mAbs
• Biosimilar mAbs
Based on Production Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
• In Vitro Production
• In Vivo Production
Based on Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
• Cancer
o Breast Cancer
o Colorectal Cancer
o Lung Cancer
o Ovarian Cancer
o Other Cancer Types
• Autoimmune Diseases
• Inflammatory Diseases
• Infectious Diseases
• Other Applications
By End User, the Asia Pacific market is segmented into the following sub-markets with annual revenue ($ bn) for 2019-2030 included in each section.
• Hospitals
• Research Institutes
• Other End Users
Geographically, the following national/local markets are fully investigated:
• Japan
• China
• South Korea
• Australia
• India
• Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
For each key country, detailed analysis and data for annual revenue ($ bn) are available for 2019-2030. The breakdown of key national markets by Source, Application, and End User over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Key Players (this may not be a complete list and extra companies can be added upon request):
Abbott Laboratories
AbbVie, Inc.
Amgen Inc.
AstraZeneca plc
Bayer AG
Bristol-Myers Squibb Company
Eli Lilly
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc
Johnson & Johnson
Merck & Co., Inc.
Mylan N.V
Norvatis AG
Pfizer
Sanofi S.A.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
1 Introduction 7
1.1 Industry Definition and Research Scope 7
1.1.1 Industry Definition 7
1.1.2 Research Scope 8
1.2 Research Methodology 11
1.2.1 Overview of Market Research Methodology 11
1.2.2 Market Assumption 12
1.2.3 Secondary Data 12
1.2.4 Primary Data 12
1.2.5 Data Filtration and Model Design 13
1.2.6 Market Size/Share Estimation 14
1.2.7 Research Limitations 15
1.3 Executive Summary 16
2 Market Overview and Dynamics 19
2.1 Market Size and Forecast 19
2.1.1 Impact of COVID-19 on World Economy 20
2.1.2 Impact of COVID-19 on the Market 22
2.2 Major Growth Drivers 24
2.3 Market Restraints and Challenges 29
2.4 Emerging Opportunities and Market Trends 32
2.5 Porter’s Fiver Forces Analysis 36
3 Segmentation of Asia Pacific Market by Source 40
3.1 Market Overview by Source 40
3.2 Human 42
3.3 Humanized 43
3.4 Chimeric 44
3.5 Murine 45
4 Segmentation of Asia Pacific Market by Category 46
4.1 Market Overview by Category 46
4.2 Branded mAbs 48
4.3 Biosimilar mAbs 49
5 Segmentation of Asia Pacific Market by Production Type 50
5.1 Market Overview by Production Type 50
5.2 In Vitro Production 52
5.3 In Vivo Production 53
6 Segmentation of Asia Pacific Market by Application 54
6.1 Market Overview by Application 54
6.2 Cancer 56
6.2.1 Breast Cancer 58
6.2.2 Colorectal Cancer 59
6.2.3 Lung Cancer 60
6.2.4 Ovarian Cancer 61
6.2.5 Other Cancer Types 62
6.3 Autoimmune Diseases 63
6.4 Inflammatory Diseases 64
6.5 Infectious Diseases 65
6.6 Other Applications 66
7 Segmentation of Asia Pacific Market by End User 67
7.1 Market Overview by End User 67
7.2 Hospitals 69
7.3 Research Institutes 70
7.4 Other End Users 71
8 Asia-Pacific Market 2019-2030 by Country 72
8.1 Overview of Asia-Pacific Market 72
8.2 Japan 75
8.3 China 78
8.4 Australia 80
8.5 India 82
8.6 South Korea 84
8.7 Rest of APAC Region 86
9 Competitive Landscape 88
9.1 Overview of Key Vendors 88
9.2 New Product Launch, Partnership, Investment, and M&A 91
9.3 Company Profiles 92
Abbott Laboratories 92
AbbVie, Inc. 94
Amgen Inc. 95
AstraZeneca plc 96
Bayer AG 97
Bristol-Myers Squibb Company 98
Eli Lilly 99
F. Hoffmann-La Roche Ltd. 100
GlaxoSmithKline Plc 101
Johnson & Johnson 102
Merck & Co., Inc. 103
Mylan N.V 104
Norvatis AG 105
Pfizer 106
Sanofi S.A. 107
RELATED REPORTS 108
List of Tables:
Table 1. Snapshot of Asia Pacific Monoclonal Antibodies Market in Balanced Perspective, 2019-2030 17
Table 2. Growth Rate of World GDP, 2020-2022 21
Table 3. World Health Spending by Region, $ bn, 2013-2020 28
Table 4. Main Product Trends and Market Opportunities in Asia Pacific Monoclonal Antibodies Market 32
Table 5. Asia Pacific Monoclonal Antibodies Market by Source, 2019-2030, $ bn 40
Table 6. Asia Pacific Monoclonal Antibodies Market by Category, 2019-2030, $ bn 46
Table 7. Asia Pacific Monoclonal Antibodies Market by Production Type, 2019-2030, $ bn 50
Table 8. Asia Pacific Monoclonal Antibodies Market by Application, 2019-2030, $ bn 54
Table 9. Asia Pacific Monoclonal Antibodies Market: Cancer Therapy by Type, 2019-2030, $ bn 57
Table 10. Asia Pacific Monoclonal Antibodies Market by End User, 2019-2030, $ bn 67
Table 11. APAC Monoclonal Antibodies Market by Country, 2019-2030, $ bn 73
Table 12. Japan Monoclonal Antibodies Market by Source, 2019-2030, $ bn 77
Table 13. Japan Monoclonal Antibodies Market by Application, 2019-2030, $ bn 77
Table 14. Japan Monoclonal Antibodies Market by End User, 2019-2030, $ bn 77
Table 15. China Monoclonal Antibodies Market by Source, 2019-2030, $ bn 79
Table 16. China Monoclonal Antibodies Market by Application, 2019-2030, $ bn 79
Table 17. China Monoclonal Antibodies Market by End User, 2019-2030, $ bn 79
Table 18. Australia Monoclonal Antibodies Market by Source, 2019-2030, $ bn 81
Table 19. Australia Monoclonal Antibodies Market by Application, 2019-2030, $ bn 81
Table 20. Australia Monoclonal Antibodies Market by End User, 2019-2030, $ bn 81
Table 21. India Monoclonal Antibodies Market by Source, 2019-2030, $ bn 83
Table 22. India Monoclonal Antibodies Market by Application, 2019-2030, $ bn 83
Table 23. India Monoclonal Antibodies Market by End User, 2019-2030, $ bn 83
Table 24. South Korea Monoclonal Antibodies Market by Source, 2019-2030, $ bn 85
Table 25. South Korea Monoclonal Antibodies Market by Application, 2019-2030, $ bn 85
Table 26. South Korea Monoclonal Antibodies Market by End User, 2019-2030, $ bn 85
Table 27. Monoclonal Antibodies Market in Rest of APAC by Country/Region, 2019-2030, $ bn 87
Table 28. Abbott Laboratories: Company Snapshot 92
Table 29. Abbott Laboratories: Business Segmentation 92
Table 30. Abbott Laboratories: Product Portfolio 93
Table 31. Abbott Laboratories: Revenue, 2018-2020, $ bn 93
List of Figures:
Figure 1. Research Method Flow Chart 11
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 14
Figure 3. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 16
Figure 4. Asia Pacific Monoclonal Antibodies Market, 2019-2030, $ bn 19
Figure 5. Impact of COVID-19 on Business 22
Figure 6. Primary Drivers and Impact Factors of Asia Pacific Monoclonal Antibodies Market 24
Figure 7. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 27
Figure 8. World Population 65 and Over, % of Total Population, 1950-2060 27
Figure 9. Primary Restraints and Impact Factors of Asia Pacific Monoclonal Antibodies Market 29
Figure 10. Investment Opportunity Analysis 33
Figure 11. Porter’s Fiver Forces Analysis of Asia Pacific Monoclonal Antibodies Market 36
Figure 12. Breakdown of Asia Pacific Monoclonal Antibodies Market by Source, 2019-2030, % of Revenue 41
Figure 13. Asia Pacific Addressable Market Cap in 2021-2030 by Source, Value ($ bn) and Share (%) 41
Figure 14. Asia Pacific Monoclonal Antibodies Market by Source: Human, 2019-2030, $ bn 42
Figure 15. Asia Pacific Monoclonal Antibodies Market by Source: Humanized, 2019-2030, $ bn 43
Figure 16. Asia Pacific Monoclonal Antibodies Market by Source: Chimeric, 2019-2030, $ bn 44
Figure 17. Asia Pacific Monoclonal Antibodies Market by Source: Murine, 2019-2030, $ bn 45
Figure 18. Breakdown of Asia Pacific Monoclonal Antibodies Market by Category, 2019-2030, % of Sales Revenue 47
Figure 19. Asia Pacific Addressable Market Cap in 2021-2030 by Category, Value ($ bn) and Share (%) 47
Figure 20. Asia Pacific Monoclonal Antibodies Market by Category: Branded mAbs, 2019-2030, $ bn 48
Figure 21. Asia Pacific Monoclonal Antibodies Market by Category: Biosimilar mAbs, 2019-2030, $ bn 49
Figure 22. Breakdown of Asia Pacific Monoclonal Antibodies Market by Production Type, 2019-2030, % of Sales Revenue 51
Figure 23. Asia Pacific Addressable Market Cap in 2021-2030 by Production Type, Value ($ bn) and Share (%) 51
Figure 24. Asia Pacific Monoclonal Antibodies Market by Production Type: In Vitro Production, 2019-2030, $ bn 52
Figure 25. Asia Pacific Monoclonal Antibodies Market by Production Type: In Vivo Production, 2019-2030, $ bn 53
Figure 26. Breakdown of Asia Pacific Monoclonal Antibodies Market by Application, 2019-2030, % of Revenue 55
Figure 27. Asia Pacific Addressable Market Cap in 2021-2030 by Application, Value ($ bn) and Share (%) 55
Figure 28. Asia Pacific Monoclonal Antibodies Market by Application: Cancer, 2019-2030, $ bn 56
Figure 29. Asia Pacific Monoclonal Antibodies Market by Cancer Type: Breast Cancer, 2019-2030, $ bn 58
Figure 30. Asia Pacific Monoclonal Antibodies Market by Cancer Type: Colorectal Cancer, 2019-2030, $ bn 59
Figure 31. Asia Pacific Monoclonal Antibodies Market by Cancer Type: Lung Cancer, 2019-2030, $ bn 60
Figure 32. Asia Pacific Monoclonal Antibodies Market by Cancer Type: Ovarian Cancer, 2019-2030, $ bn 61
Figure 33. Asia Pacific Monoclonal Antibodies Market by Cancer Type: Other Cancer Types, 2019-2030, $ bn 62
Figure 34. Asia Pacific Monoclonal Antibodies Market by Application: Autoimmune Diseases, 2019-2030, $ bn 63
Figure 35. Asia Pacific Monoclonal Antibodies Market by Application: Inflammatory Diseases, 2019-2030, $ bn 64
Figure 36. Asia Pacific Monoclonal Antibodies Market by Application: Infectious Diseases, 2019-2030, $ bn 65
Figure 37. Asia Pacific Monoclonal Antibodies Market by Application: Other Applications, 2019-2030, $ bn 66
Figure 38. Breakdown of Asia Pacific Monoclonal Antibodies Market by End User, 2019-2030, % of Revenue 68
Figure 39. Asia Pacific Addressable Market Cap in 2021-2030 by End User, Value ($ bn) and Share (%) 68
Figure 40. Asia Pacific Monoclonal Antibodies Market by End User: Hospitals, 2019-2030, $ bn 69
Figure 41. Asia Pacific Monoclonal Antibodies Market by End User: Research Institutes, 2019-2030, $ bn 70
Figure 42. Asia Pacific Monoclonal Antibodies Market by End User: Other End Users, 2019-2030, $ bn 71
Figure 43. Breakdown of APAC Monoclonal Antibodies Market by Country, 2019 and 2030, % of Revenue 73
Figure 44. Contribution to APAC 2021-2030 Cumulative Market by Country, Value ($ bn) and Share (%) 74
Figure 45. Monoclonal Antibodies Market in Japan, 2019-2030, $ bn 76
Figure 46. Monoclonal Antibodies Market in China, 2019-2030, $ bn 78
Figure 47. Monoclonal Antibodies Market in Australia, 2019-2030, $ bn 80
Figure 48. Monoclonal Antibodies Market in India, 2019-2030, $ bn 82
Figure 49. Monoclonal Antibodies Market in South Korea, 2019-2030, $ bn 84
Figure 50. Monoclonal Antibodies Market in Rest of APAC, 2019-2030, $ bn 86
Figure 51. Growth Stage of Asia Pacific Monoclonal Antibodies Industry over the Forecast Period 88